Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck
Public ClinicalTrials.gov record NCT00216138. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40
Study identification
- NCT ID
- NCT00216138
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Enrollment
- 19 participants
Conditions and interventions
Conditions
Interventions
- Docetaxel Drug
- Capecitabine Drug
- Premedication Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2004
- Primary completion
- Aug 31, 2007
- Completion
- Aug 31, 2007
- Last update posted
- May 1, 2011
2004 – 2007
United States locations
- U.S. sites
- 18
- U.S. states
- 7
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Helen F. Graham Cancer Center | Newark | Delaware | 19713 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Elkhart Clinic | Elkhart | Indiana | 46515 | — |
| Oncology Hematology Associates of SW Indiana | Evansville | Indiana | 47714 | — |
| Fort Wayne Oncology & Hematology, Inc | Fort Wayne | Indiana | 46815 | — |
| Center for Cancer Care at Goshen Health System | Goshen | Indiana | 46527 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202 | — |
| Quality Cancer Center (MCGOP) | Indianapolis | Indiana | 46202 | — |
| Arnett Cancer Care | Lafayette | Indiana | 47904 | — |
| Medical Consultants, P.C. | Muncie | Indiana | 47303 | — |
| Center for Cancer Care, Inc., P.C. | New Albany | Indiana | 47150 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46601 | — |
| Providence Medical Group | Terre Haute | Indiana | 47802 | — |
| AP&S Clinic | Terre Haute | Indiana | 47804 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Center for Hematology-Oncology of S Michigan | Jackson | Michigan | 49201 | — |
| Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Methodist Cancer Center | Omaha | Nebraska | 68114 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00216138, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2011 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00216138 live on ClinicalTrials.gov.